TY - JOUR T1 - Ambrisentan for pulmonary fibrosis JF - Thorax JO - Thorax SP - 489 LP - 489 DO - 10.1136/thoraxjnl-2013-204438 VL - 69 IS - 5 AU - Ravi Punwani Y1 - 2014/05/01 UR - http://thorax.bmj.com/content/69/5/489.abstract N2 - This randomised, double-blind, placebo-controlled study is one of the largest multicentre studies investigating whether ambrisentan (an endothelin A receptor antagonist) reduces the rate of idiopathic pulmonary fibrosis (IPF) progression. The investigators compared ambrisentan (more commonly used in the treatment of pulmonary hypertension (PH)) with placebo on the basis of preclinical studies suggesting endothelin … ER -